092730 — NeoPharm Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesAdventurousSmall CapSuper Stock

Annual income statement for NeoPharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	81,625	87,931	85,033	97,105	119,014
Cost of Revenue
Gross Profit	58,642	62,386	58,380	65,385	74,027
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	59,723	65,511	63,601	71,811	94,364
Operating Profit	21,902	22,420	21,433	25,294	24,650
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	22,936	23,836	23,323	29,373	30,209
Provision for Income Taxes
Net Income After Taxes	18,131	17,713	17,027	23,213	23,065
Minority Interest
Net Income Before Extraordinary Items
Net Income	18,131	17,713	17,027	23,213	23,065
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	18,131	17,713	17,027	23,213	23,065
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,149	1,133	1,088	1,484	1,471
Dividends per Share